No description available.

Die systemische Verabreichung von Amoxizillin/Metronidazol (AM) als Zusatz zu Scaling/Root planing (SRP) in der Behandlung der generalisierten Aggressiven Parodontitis (gAP) führt zu guten klinischen und mikrobiologischen Ergebnissen. Die lokale antiseptische Zusatzmedikation mit Chlorhexidin in einem Controlled-Delivery-Device (PerioChip, PC) verbessert das Ergebnis von SRP in der Behandlung der Chronischen Parodontitis. Die Anwendung in der Behandlung der gAP ist bisher noch nicht untersucht worden. Ziele: Der Effekt von PC als Zusatz zu SRP in der Therapie der gAP wurde untersucht. Die Wirksamkeit wurde mit der Standardmedikation AM verglichen. Neben klinischen Parametern wurde die Konzentration des Entzündungsmarkers Calprotectin in der Sulkusflüssigkeit (SF) bestimmt. Material/Methode: 36 gAP-Patienten (18/Gruppe, 35+/-4 Jahre) wurden mit SRP und randomisiert entweder mit AM oder PC behandelt. Zur Baseline, 3 und 6 Monate nach SRP wurden die klinischen Parameter PD, CAL, BoP, Pus erhoben sowie SF-Proben tiefer und flacher Referenzstellen entnommen. Die Calprotectin-Konzentration in der SF wurde mittels ELISA bestimmt. Ergebnisse: 3 Monate nach SRP zeigten beide Gruppen signifikante Verbesserungen der klinischen Parameter, wobei noch keine Unterschiede zwischen den Gruppen bestanden. Während die AM-Gruppe stabil blieb, verschlechterten sich mehrwurzelige Zähne und tiefe Referenzstellen der PC-Gruppe wieder signifikant. Nach 6 Monaten wies die AM-Gruppe signifikant mehr CAL-Gewinn und PD-Reduktion auf. Pus war nur noch in der PC-Gruppe nachweisbar. Die Calprotectin-Konzentration war zwar in beiden Gruppen signifikant gesunken, Unterschiede zwischen den Gruppen bestanden jedoch aufgrund hoher Standardabweichungen nicht. Schlussfolgerung: AM zeigte eine bessere klinische Wirksamkeit und Langzeitstabilität als PC. Aufgrund großer interindividueller Variabilität spiegelte die SF-Konzentration von Calprotectin die klinischen Unterschiede nicht wider. / Adjunctive systemic administration of amoxicillin/metronidazole (AM) in generalized aggressive periodontitis (gAP) therapy results in good clinical and microbiological outcome. Adjunctive use of chlorhexidine within a controlled-delivery-device (PerioChip, PC) improves the outcome of scaling/root planing (SRP) in chronic periodontitis therapy. Its effect in the treatment of gAP has not been evaluated. Aims: The effect of adjunctive use of PC in the treatment of gAP was investigated. Efficacy of PC was compared to the standard treatment with AM. Clinical parameters and the concentration of the inflammation marker calprotectin within gingival crevice fluid (GCF) were measured. Material/methods: 36 gAP patients (18/group, 35+/-4 years) were treated by SRP either AM or PC. Clinical parameters PD, CAL, BoP and Pus were recorded at baseline, 3 and 6 months after therapy. GCF was sampled at deep and shallow reference sites and the concentration of calprotectin was measured by ELISA. Results: Both groups showed significant improvements of clinical parameters 3 months after SRP, however differences between groups were not significant. While the AM-group remained clinically stable, multirooted teeth and deep reference sites of the PC-group showed significant deterioration again. 6 months after SRP, the AM-group showed significant more CAL gain and PD reduction. Pus was detectable in the PC group only. The concentration of calprotectin in GCF had significantly decreased in both groups; however differences between groups were not significant due to high standard deviations. Conclusion: AM showed higher efficacy in terms of clinical treatment outcome and long-term stability than PC. Due to high interindividual variability, GCF-concentrations of calprotectin failed to reflect clinical differences.

Chlamydia trachomatis is the most common sexually transmitted bacterial disease agent worldwide, and, though frequently asymptomatic, can cause extreme pathology including infertility. Chlamydial species exhibit a unique biphasic developmental cycle. Once attached to a cell surface, infectious elementary bodies (EB) are internalized within an inclusion, the membrane-bound structure in which EB transform to noninfectious, replicable reticulate bodies (RB). After multiple rounds of division, RB condense to form EB, which are released and can infect new host cells. In culture, exposure to stressors, such as beta-lactam antibiotics, induce chlamydiae to reversibly detour from normal development into a noninfectious, viable state termed persistence. Cell culture data suggest that persistent forms are resistant to azithromycin (AZM), a front-line antibiotic, and are able to alter the host transcriptome. Though persistence has been described in culture for over 50 years, whether or not it: i) occurs in vivo; and ii) influences chlamydial pathogenesis, transmission and therapy has remained unresolved. To address these questions, we developed an animal model of persistent chlamydial infection using amoxicillin (AMX) treatment. AMX exposure decreased shedding of infectious chlamydiae in C. muridarum-infected mice without affecting chlamydial viability, demonstrating the presence of persistent chlamydiae. Shedding of infectious EB resumed following AMX cessation. Shedding data and microarray analyses suggested that host immunity might limit chlamydia’s exit from persistence in our model. Thus, we hypothesized that cyclophosphamide (CTX) treatment would increase the magnitude of chlamydial shedding observed after AMX-treatment cessation. CTX treatment increased post-AMX shedding by more than 10-fold compared to AMX-only controls. To determine whether persistent chlamydiae are resistant to antibiotic eradication in vivo, we induced persistence by administering AMX and treated mice with various AZM dosing regimes. Persistently infected mice demonstrated increased treatment failure following AZM therapy compared to productively infected controls. These data suggest that persistent chlamydiae are refractory to treatment in vivo and provide an explanation for the observation that treatment fails in some patients. In addition to creating the first fully characterized, experimentally tractable, in vivo model of chlamydial persistence, these experiments provide evidence that persistent/stressed chlamydial forms may serve as a long-term reservoir of infectious organisms in vivo.